Hypervascularity is not only commonly found in human HCC, but many treatments for advanced HCC also target angiogenesis, such as the well-known multikinase inhibitor, sorafenib, which inhibits angiogenesis via the VEGF pathway [74,75]. Here, VEGFA is linked to hepatocellular carcinoma.